These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25098097)

  • 21. Pathophysiology of gastro-oesophageal reflux disease.
    De Giorgi F; Palmiero M; Esposito I; Mosca F; Cuomo R
    Acta Otorhinolaryngol Ital; 2006 Oct; 26(5):241-6. PubMed ID: 17345925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of liquid meals with different volumes on gastroesophageal reflux disease.
    Wu KL; Rayner CK; Chuah SK; Chiu YC; Chiu KW; Hu TH; Chiu CT
    J Gastroenterol Hepatol; 2014 Mar; 29(3):469-73. PubMed ID: 24712047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis.
    Pauwels A; Blondeau K; Dupont LJ; Sifrim D
    Am J Gastroenterol; 2012 Sep; 107(9):1346-53. PubMed ID: 22777342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
    Mönnikes H; Schwan T; van Rensburg C; Straszak A; Theek C; Sander P; Lühmann R
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1279-89. PubMed ID: 22486552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esophageal impedance monitoring and pathophysiology of gastroesophageal reflux disease.
    Sifrim D
    Verh K Acad Geneeskd Belg; 2006; 68(3):151-78. PubMed ID: 16796016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of prolonged gastric distention on lower esophageal sphincter function and gastroesophageal reflux.
    Hirsch DP; Mathus-Vliegen EM; Dagli U; Tytgat GN; Boeckxstaens GE
    Am J Gastroenterol; 2003 Aug; 98(8):1696-704. PubMed ID: 12907321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reflux inhibitors: a new approach for GERD?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):685-9. PubMed ID: 18771751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced tLESR elicitation in response to gastric distension in fundoplication patients.
    Scheffer RC; Tatum RP; Shi G; Akkermans LM; Joehl RJ; Kahrilas PJ
    Am J Physiol Gastrointest Liver Physiol; 2003 May; 284(5):G815-20. PubMed ID: 12684212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease.
    Sifrim D; Holloway R; Silny J; Tack J; Lerut A; Janssens J
    Am J Gastroenterol; 2001 Mar; 96(3):647-55. PubMed ID: 11280529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
    Beaumont H; Boeckxstaens GE
    Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
    Johnson DA; Levy BH
    Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of gastro-esophageal reflux disease: the new kids to block.
    Blondeau K
    Neurogastroenterol Motil; 2010 Aug; 22(8):836-40. PubMed ID: 20663054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease.
    Savarino E; Gemignani L; Pohl D; Zentilin P; Dulbecco P; Assandri L; Marabotto E; Bonfanti D; Inferrera S; Fazio V; Malesci A; Tutuian R; Savarino V
    Aliment Pharmacol Ther; 2011 Aug; 34(4):476-86. PubMed ID: 21671968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastro-oesophageal reflux in children.
    Taminiau JA
    Scand J Gastroenterol Suppl; 1997; 223():18-20. PubMed ID: 9200301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The relationship between lower esophageal sphincter motility and function with gastroesophageal reflux disease].
    Wang H; Liu B
    Zhonghua Nei Ke Za Zhi; 2004 Oct; 43(10):750-2. PubMed ID: 15631827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors.
    Hershcovici T; Fass R
    Curr Opin Gastroenterol; 2010 Jul; 26(4):367-78. PubMed ID: 20571388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.